ethnic minorities, are under-represented among participants in cancer clinical trials [4, 5] . Since race is primarily a sociocultural and political construct rather than an expression of significant biological differences [6] , clinical trials may generally not be expected to show racial differences in the biologic response to an intervention. However, there are several arguments in favor of inclusion of underrepresented populations in clinical trials [7] . First, when there is a well-formed hypothesis regarding racial differences in the response to an intervention, the investigators should plan a clinical trial with statistical power to detect those differences; and techniques to adequately recruit minority populations can be critical to that effort. A second reason for the inclusion of under-represented populations in clinical trials is to facilitate subgroup analyses for hypothesis generation. In the new era of targeted therapies, whose effectiveness in a population may depend on the frequency of unknown polymorphisms [8] , studying populations with different prevalences of relevant genotypic variants will become increasingly important [9] . Having adequate and well-defined subgroups can also enable the combination and comparison of data across studies. The third argument is that equitable representation results in equitable distribution of the benefits and risks of participation in clinical trials [10] . This argument also supports targeted efforts to enhance representation of population subgroups in proportion to their burden of disease, thereby increasing the generalizability of the trial results.
There are critical gaps, however, in our understanding of which strategies are effective in increasing recruitment of medically underserved populations to clinical trials. In this issue of the Journal, Ford et al. report the results of the AAMEN (African American Men's) project [11] , a randomized trial that compared strategies of increasing intensity, for recruitment of African American men into the PLCO (Prostate, Lung, Colorectal and Ovarian) cancer screening trial. Most previous studies of recruitment barriers to cancer prevention and treatment trials have used focus groups, case series or surveys as their methods of assessment; and to date, there have been few USbased studies comparing two or more intervention strategies for accrual to cancer prevention or treatment trials. The AAMEN project is one of the rare USbased randomized controlled clinical trials to evaluate the relative effectiveness of different recruitment strategies for cancer prevention trials.
The AAMEN project presents several innovative features, including the method used for assignment of socioeconomic status, a critical factor in the evaluation of strategies for accrual to clinical trials [12] . Most studies of recruitment strategies targeting racial/ethnic minority populations, including African Americans, provide only limited information regarding the participants' socioeconomic status. In contrast, the AAMEN study investigators geocoded home addresses by census block group to determine average household income. This use of spatially defined data at a distinct geographical level is a valid and reliable method for assigning socioeconomic status, overcoming the substantial measurement problems of self-reported income [13] .
In a systematic review, Prescott et al. [14] discussed potential barriers to recruitment as well as opportunities to improve recruitment outcomes. These barriers may be categorized as follows: 1) additional demands on participants (e.g., extra procedures and time pressures, travel problems and extra costs); 2) patient preferences (e.g., wish not to change medications or take placebo; concern about medications); 3) worry about uncertainty (e.g., fear of the unknown); and 4) concern about information and consent (e.g., need for effective trial educational presentation to increase awareness, need for appropriate language and need for information to be presented at the appropriate literacy level). It is a sobering statistic that 97% (12 024/12 400) of eligible men in the AAMEN Project refused to participate in the PLCO trial. This illustrates both the challenge of recruitment to a long-term (23 years) clinical trial, irrespective of race/ethnicity [11] and the known challenge of accrual of African American men to cancer clinical trials [4] . In the three intervention arms of the AAMEN project that yielded statistically similar results, the common feature was that men had to mail the consent forms; and in two of those three arms, they had to mail the baseline questionnaire as well. The statistically superior intervention featured recruitment at local churches through face-to-face interviews. By gathering baseline information and obtaining consent to participate in the study at a single session, AAMEN study investigators may have been able to discuss patient concerns more fully. However, for many potential participants this intervention strategy may have been insufficient to overcome medical distrust and other barriers [15] .
Overall, recruitment of medically underserved populations into clinical trials is a resource intensive effort [16] . The article by Ford and colleagues is an important contribution not only because it demonstrates that face-to-face recruitment is superior to the other, less intensive, recruitment strategies, but it provides a reliable estimate of the additional yield that can be expected for the substantial additional expenditure of resources. This has not been examined previously in a US-based randomized clinical trial. Clinical trials are expensive and most of the literature on recruitment represents success stories of investigators who overcame accrual problems. The AAMEN project illustrates the possibility of reaching conclusions about preferred recruitment methods for a specific population within the context of another randomized controlled trial, arming trialists with rigorously evaluated recruitment strategies for difficult-to-reach populations.
